Real-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product
Claude Bergeron, M.Sc., A.S.A.
Advertisement
Senior Director, Pharmaceutical & Biotech Solutions, McKesson Specialty Health
Articles by Claude Bergeron, M.Sc., A.S.A.
Advertisement
Latest Updated Articles
- Outcomes Data: A Critical Insight for Market Access
Published: October 9th 2013 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Bob Mauch: Strengthening the Chain
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
